(From the July 2013 Issue of MedStat)
The following actions were taken at the June 6 Pharmacy & Therapeutics Committee meeting. For more detailed information, contact Shelly Morvay at Shelly.Morvay@NationwideChildrens.org.
Request to use TOBI Podhaler samples in the Pulmonary Clinic was APPROVED.
Medication stock lists were APPROVED for Adolescent Clinic, Nephrology Clinic, Primary Care Clinics and Pulmonary Clinic.
Six month reviews were presented for abatacept, bosentan, iloprost, meclizine, and rifapentine. All medications were APPROVED to remain on the Formulary.
Azelastine (ASTEPRO) 0.15% nasal spray was ADDED to the Formulary. Astelin will be REMOVED from the Formulary. The Astepro monograph will be posted on the Pharmacy Department intranet site. Astepro is indicated for children ages 12 years and older and is expected to be better tolerated than Astelin.
Gadofosveset trisodium (Ablavar) was ADDED to the Formulary. The monograph will be posted on the Pharmacy Department intranet site.
The following drug cards were APPROVED: GNKG168 (investigational), ondansetron and moxetumomab pasudotox (investigational). The drug cards will be posted in the online drug card database.
myChildren’s mobile app
iPhone and Android.